Loading…
← CockpitCompetitor Analysis › 128940.KS HanmiPharmOpen in the cockpit ↗

HanmiPharm128940.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.

Momentum leader 92
Mkt cap
$3.95B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$45.1M
20-day average traded
Fwd P/E
15.0×
forward earnings
ROIC−WACC
+4.9 pp
WACC 6.0%
Hurdle
-3 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · KRW₩438,500
1D-2.2%
1W-13.8%
1M+15.8%
3M+10.0%
6M-2.5%
YTD-2.6%
1Y-0.8%
ATR %7.0%
52w lowhigh32.0% off high

What HanmiPharm does

Major Korean R&D-focused pharmaceutical company known for global licensing deals in diabetes/obesity and oncology drugs.

Sells prescription drugs in Korea, often combination pills built from existing molecules, through hospitals and wholesalers; that steady business funds research. Licensing deals with larger drugmakers add lumpy milestone payments tied to partners' trial progress. Hanmi Science is the holding company above it.

Products and services

  • Branded generic drugs
  • Novel drug pipeline (GLP-1, oncology)
  • Cardiovascular drugs

Customers

  • Hospitals/pharmacies (Korea)
  • Global pharma licensing partners

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics and R&D pipeline
  • Global out-licensing

What could go right

  • Global GLP-1/obesity licensing deals
  • Branded-generic portfolio growth

What could go wrong

  • Clinical-trial/licensing-milestone risk
  • Domestic drug-pricing regulation

Moat: narrow (IP / patents, brand). One of few Asian pharma companies with a globally licensed novel-drug pipeline.

Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 2,382

Named competitors

HanmiPharm at a glance

Size HanmiPharm (128940.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $3.95B, the 89th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩438,500 on 18 Nov 2026.

Performance Over six months the shares fell 2.5%, against +3.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 19 in its peer set.

Growth Revenue grew 13.9% over the last twelve months (peer median +7.9%); the operating margin is 15.7% (peer median 19.4%).

Valuation It trades at 15.0× forward earnings against a peer median of 21.9× (3rd cheapest of 14).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.9 points above its cost of capital (6.0% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 104128940.KS 93
Six months, rebased to 100: HanmiPharm against the median of its 20 peers (local-currency closes).

HanmiPharm financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.67T₩1.55T₩1.50T₩1.49T₩1.33T
Revenue growth—+3%0%+12%—
Gross profit₩982B₩880B₩827B₩836B₩730B
EBITDA₩362B₩323B₩310B₩323B₩250B
Net income₩189B₩170B₩121B₩146B₩82.8B
Free cash flow₩172B₩130B₩154B₩189B₩133B
Capital expenditure₩96.1B₩80.7B₩67.0B₩47.7B₩69.4B
Total debt₩385B₩434B₩497B₩573B₩678B

Quarterly statements and history in the cockpit →

HanmiPharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%DFTX6883360001004536000513600329ROVITARSXENESLSOGN0022943320CAMXWOCKPHARMA128940.KS6-month return →1-month return →
Up and to the right = strong over both horizons. HanmiPharm is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×6883360001004536000513600329ROVIOGN0022946005213320CAMXAJANTPHARM128940.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HanmiPharm is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%3015696883364536000513600329ROVITARS600521CAMXAJANTPHARMWOCKPHARMA128940.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HanmiPharm is the large dot.

HanmiPharm competitors and peer comparison

Head to head with its named competitors (128940.KS vs 000100.KS vs 326030.KS vs NOVO-B.CO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
HanmiPharm 128940.KS$3.95B-2%+14%16%15.0×4.7%
Yuhan 000100.KS$4.11B-10%+8%6%40.4×n/a
SKBP 326030.KS$5.03B-16%+37%38%21.5×-4.4%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%

How HanmiPharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HanmiPharm against its 20 peers (data as of 18 Nov 2026)
Measure128940.KSPeer medianRank in peer set
1-month return+15.8%+2.6%5th highest of 21
6-month return-2.5%+3.5%7th lowest of 19
Distance from 52-week high-32.0%-23.4%8th lowest of 21
Revenue growth (TTM)+13.9%+7.9%7th highest of 18
Operating margin15.7%19.4%7th lowest of 17
Forward P/E15.0×21.9×3rd cheapest of 14
Growth the price implies (Req g, 7 yrs)4.7%6.4%8th least demanding of 16
Growth delivered (Del g)+7.5%+5.9%8th highest of 16
Hurdle (Req g minus delivered)-2.9 pp-8.2 pp7th most demanding of 16
ROIC minus cost of capital+4.9 pp+6.9 pp9th lowest of 18
EV / EBITDA15.2×22.9×4th cheapest of 10
Net debt / EBITDA0.2×-0.3×4th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a

Questions

Who are HanmiPharm's main competitors?
Named competitors: Yuhan (000100.KS), SK Biopharmaceuticals (326030.KS), Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY). The cockpit's measured peer set (industry) also includes Novast Laboratories (301569.SZ), Definium Therapeutics (DFTX), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), Yuhan (000100.KS), Santen Pharmaceutical (4536.T), Livzon Pharmaceutical (000513.SZ).
Is HanmiPharm expensive compared with its peers?
On forward p/e it trades at 15.0× against a peer median of 21.9×, 3rd cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has HanmiPharm stock performed?
Over six months to 18 Nov 2026 the shares returned -2.5% against +3.5% for the median peer; over one year -0.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.